News

Video

What is DNA and RNA Testing in Biomarker Testing?

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
2 experts in this video
2 experts in this video
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Tracy George, MD
Related Content
The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/18

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
December 13th 2024

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC
December 13th 2024

Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBC

Breast Cancer | Image Credit: © Axel Kock – stock.adobe.com
December 13th 2024

Perioperative Atezolizumab Plus Chemo Does Not Improve EFS in TNBC